Literature DB >> 18007663

Molecular characteristics of immunogenic cancer cell death.

A Tesniere1, T Panaretakis, O Kepp, L Apetoh, F Ghiringhelli, L Zitvogel, G Kroemer.   

Abstract

Apoptotic cell death is initiated by a morphologically homogenous entity that was considered to be non-immunogenic and non-inflammatory in nature. However, recent advances suggest that apoptosis, under certain circumstances, can be immunogenic. In particular, some characteristics of the plasma membrane, acquired at preapoptotic stage, can cause immune effectors to recognize and attack preapoptotic tumor cells. The signals that mediate the immunogenicity of tumor cells involve elements of the DNA damage response (such as ataxia telangiectasia mutated and p53 activation), elements of the endoplasmic reticulum stress response (such as eukaryotic initiation factor 2alpha phosphorylation), as well as elements of the apoptotic response (such as caspase activation). Depending on the signal-transduction pathway, tumor cells responding to chemotherapy or radiotherapy can express 'danger' and 'eat me' signals on the cell surface (such as NKG2D ligands, heat-shock proteins and calreticulin) or can secrete/release immunostimulatory factors (such as cytokines and high-mobility group box 1) to stimulate innate immune effectors. Likewise, the precise sequence of such events influences the 'decision' of the immune system to mount a cognate response or not. We therefore anticipate that the comprehension of the mechanisms governing the immunogenicity of cell death will have a profound impact on the design of anticancer therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18007663     DOI: 10.1038/sj.cdd.4402269

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  147 in total

1.  Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.

Authors:  Eleonora Reginato; Peter Wolf; Michael R Hamblin
Journal:  World J Immunol       Date:  2014-03-27

Review 2.  Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?

Authors:  Ryuichi Kanai; Hiroaki Wakimoto; Tooba Cheema; Samuel D Rabkin
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

Review 3.  Pharmacologically directed cell disposal: labeling damaged cells for phagocytosis as a strategy against acute pancreatitis.

Authors:  Michael Chvanov; Ole H Petersen; Alexei V Tepikin
Journal:  Mol Interv       Date:  2010-04

Review 4.  HMGB1 and microparticles as mediators of the immune response to cell death.

Authors:  David S Pisetsky; Julie Gauley; Anirudh J Ullal
Journal:  Antioxid Redox Signal       Date:  2011-05-05       Impact factor: 8.401

5.  Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells.

Authors:  Irena Adkins; Lenka Sadilkova; Nada Hradilova; Jakub Tomala; Marek Kovar; Radek Spisek
Journal:  Oncoimmunology       Date:  2017-03-31       Impact factor: 8.110

Review 6.  In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology.

Authors:  Chenkai Mao; Michael-Joseph Gorbet; Akansha Singh; Ashish Ranjan; Steven Fiering
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

Review 7.  The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Authors:  James W Hodge; Andressa Ardiani; Benedetto Farsaci; Anna R Kwilas; Sofia R Gameiro
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

Review 8.  What's the place of immunotherapy in malignant mesothelioma treatments?

Authors:  Marc Grégoire
Journal:  Cell Adh Migr       Date:  2010-01-30       Impact factor: 3.405

Review 9.  Autophagy: molecular machinery, regulation, and implications for renal pathophysiology.

Authors:  Sudharsan Periyasamy-Thandavan; Man Jiang; Patricia Schoenlein; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2009-03-11

10.  Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer.

Authors:  Ravi A Madan; Thomas Schwaab; James L Gulley
Journal:  J Natl Compr Canc Netw       Date:  2012-12-01       Impact factor: 11.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.